Search Results

Business

ArsenalBio Snags Mega $325M Series C Round With Backing from Nvidia, Regeneron

Proceeds from the oversubscribed financing will be used to advance ArsenalBio’s lead programs, which include a handful of solid tumor cell therapy candidates.

September 4, 2024

·

1 min read

·

Annalee Armstrong

Press Releases

ArsenalBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025

·

1 min read

Biotech Bay

ArsenalBio Announces Presentation of Four Abstracts at ASGCT Annual Meeting Highlighting New Mechanisms for Leveraging CAR T Cells to Address Solid Tumor Cancers

Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the presentation of four abstracts at the American Society of Gene + Cell Therapy (ASGCT) annual meeting in Baltimore, Md., May 7-11, 2024.

May 6, 2024

·

5 min read

Press Releases

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors

January 14, 2025

·

3 min read

Biotech Bay

ArsenalBio to Participate in Upcoming Investor Conferences

ArsenalBio today announced that Company leadership will participate in two upcoming virtual investor conferences: Piper Sandler 33rd Annual Virtual Healthcare Conference Format: On-Demand Presentation Date: November 29 – December 2, 2021.

November 19, 2021

·

1 min read

Business

ArsenalBio Announces Expansion of Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors

Arsenal Biosciences, Inc. today announced that Bristol Myers Squibb (NYSE:BMY) has exercised an option to initiate a new program, expanding its strategic collaboration with ArsenalBio to discover and advance next-generation T cell therapies for the treatment of solid tumors.

January 10, 2022

·

3 min read

Biotech Bay

ArsenalBio to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

ArsenalBio, a privately held programmable cell therapy company focused on building advanced CAR T therapies for solid tumors, today announced that members of its senior management team are scheduled to participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 12:30 p.m. ET.

September 8, 2021

·

1 min read

Biotech Bay

ArsenalBio Announces Presentation of Six Abstracts at AACR Annual Meeting Highlighting Programmable Cell Therapy Progress

Company to share preclinical data on the use of integrated circuit T cells for the development of cell therapies for the treatment of kidney and other solid tumor cancers.

April 14, 2023

·

7 min read

Biotech Bay

ArsenalBio Announces Participation in Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

ArsenalBio today announced that it will present pre-clinical data from AB-X, the company’s integrated circuit T cell therapy program for the treatment of ovarian cancer (OC), at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting taking place November 10-14, 2021

November 4, 2021

·

2 min read

Business

ArsenalBio Announces Appointment of John Schroer as Chief Financial Officer and Tim Sirichoke as Chief Technical Operations Officer

-- Follows recent appointments of Barbara Kosacz and Matthew Fust to ArsenalBio’s Board of Directors and Ken Drazan as Chairman of the Board -- -- Expansion of leadership will support programmable cell therapy pioneer’s continued pipeline, business and operations scale-up --

March 8, 2021

·

4 min read